Form 4: Abbott Director Alpern Boosts Stake with Stock Units

Abbott Laboratories Director Robert J. Alpern acquired 62 stock equivalent units, increasing his beneficial ownership to 10,409 units.

Summary

• Director Robert J. Alpern acquired 62 stock equivalent units of Abbott Laboratories (ABT).
• The transaction occurred on December 31, 2025.
• These units were credited as director fees and are held in a grantor trust.
• Each unit is equivalent to one common share, with the underlying common shares valued at $125.29 per share at the time of acquisition.
• Following this acquisition, Alpern beneficially owns a total of 10,409 stock equivalent units.
• The balance includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 6

Explanation: The acquisition of stock equivalent units by a director, even as compensation, is generally a positive signal as it increases insider ownership and aligns interests with shareholders. The amount is relatively small in the context of the company's market capitalization, hence a moderate positive score.

Positives

• Director Robert J. Alpern increased his beneficial ownership in Abbott Laboratories by acquiring 62 stock equivalent units.
• Insider acquisition, even through compensation, can signal confidence in the company's future performance and aligns director interests with shareholders.

Future Outlook

NA

Industry Context

This transaction is a routine disclosure of director compensation in the form of stock equivalent units for a major healthcare company, Abbott Laboratories. It reflects standard corporate governance practices for executive and director remuneration, aligning their interests with shareholders.

Comparison to Industry Standards

• The practice of compensating directors with stock equivalent units is common across the healthcare and broader S&P 500 industries, aligning director interests with long-term shareholder value.
• The specific number of units acquired (62) and the total beneficial ownership (10,409 units) are specific to Director Alpern's compensation structure and tenure at Abbott Laboratories, and would need to be compared against similar-sized companies and director roles for a detailed benchmark.

Related Party Transactions

• Acquisition of 62 stock equivalent units by Director Robert J. Alpern as part of his director fees, credited to a grantor trust, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through increased equity ownership.
• Employees/Customers/Suppliers/Creditors: No direct immediate impact from this routine insider transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine acquisition of stock equivalent units by a director as part of their compensation. While it indicates continued insider ownership and alignment, the transaction size is not significant enough to warrant a change in investment recommendation for a large-cap stock like Abbott Laboratories. The filing provides no new fundamental information to alter the investment thesis, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Abbott Laboratories, ABT, Form 4, Insider Trading, Director Compensation, Stock Equivalent Units, Beneficial Ownership, Healthcare, Medical Devices